Introduction: Hereditary Hemorrhagic Telangiectasia (HHT) is an autosomal dominant genetic disease characterized by the presence of arteriovenous malformations in the nasal mucosa, the tips of fingers, and sometimes in the lungs, the gastrointestinal tract, the liver, the pancreas, the marrow and the brain. Its treatment is based on symptomatic control measures, but recently, the administration of anti-vascular endothelial growth factor (VEGF) molecules has been proposed as a treatment alternative, especially in patients with recurrent bleeding.Case presentation: The case of a 67-year-old man diagnosed with HHT and suffering from potentially life-threatening gastrointestinal GI bleeding is presented. The patient underwent several esophagogastric cauterization procedures but not positive outcomes were obtained, so he had to go to the Emergency Service of the hospital multiple times due to having low levels of hemoglobin (as low as 3.5g/dl). A bevacizumab based treatment was started by using a novel dosage regimen consisting of the administration of 6 5mg/kg bevacizumab dosages every 14 days. During the first week of treatment, hemoglobin levels increased to 14g/dl and the condition was stabilized.Conclusions: The findings reported here suggest that bevacizumab may be a therapeutic choice to be considered when treating patients with recurrent and refractory GI bleeding caused by HHT. However, a larger sample is required to determine if administering this medication is safe for these patients, as well as the appropriate dosage.
Acute myeloid leukemia (AML) is a malignant disorder of the hematopoietic stem and progenitor cells, which results in the build-up of immature blasts in the bone marrow and eventually in the peripheral blood of affected patients. Accurately assessing a patient´s prognosis is very important for clinical management of the disease, which is why there are several prognostic factors such as age, performance status at diagnosis, platelet count, serum creatinine and albumin that are taken into account by the clinician when deciding the course of treatment. However, proteomic changes related to treatment response in this patient group have not been widely explored. Here, we make available a set of 22 two-dimensional gel electrophoresis (2DGE) images obtained from the peripheral blood samples of 11 patients with AML, taken at the time of diagnosis and after induction therapy (approximately 21–28 days after starting treatment). The same set of 2DGE images is also made available after a preprocessing stage (an additional 22 2DGE pre-processed images), which was performed using algorithms developed in Python, in order to improve the visualization of characteristic spots and facilitate proteomic analysis of this type of images.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.